The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 41, 44, 46, 48 or 78 as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the EPHA4 e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.
